Choose a Drug ! Aciphex Acomplia Actos Acyclovir Allegra Alli Diet Drug Altace Ambien Amoxicillin Atenolol Ativan Augmentin Avandia Avapro Baclofen Bactrim Biaxin Celebrex Celexa Cephalexin Champix Cialis Cipro Claritin D Clomid Coreg Depakote Diflucan Dilantin Diovan Doxycycline Effexor XR Elavil Estradiol Flomax Flonase Fluoxetine Folic Acid Fosamax Glucophage Hydroxyzine Ibuprofen Imitrex Keflex Lamisil Lasix Levaquin Levitra Lexapro Lipitor Mobic Naproxen Neurontin Nexium Norvasc Omeprazole Paxil Plavix Premarin Prevacid Promethazine Propecia Proscar Protonix Reductil Reglan Remeron Risperdal Singulair Sonata Synthroid Tamiflu Topamax Trazodone Ultra "C" tabs Ultra "L" tabs Ultra "V" tabs Ultram Viagra Wellbutrin Xenical Zithromax Zocor Zoloft Zyban Zyprexa Zyrtec

September 2007 August 2007 July 2007 June 2007 May 2007 April 2007 March 2007 February 2007 January 2007 December 2006 November 2006 October 2006 September 2006 August 2006 July 2006 June 2006 May 2006 April 2006 March 2006 February 2006

Opt-in for Free Newsletter, special discount offers, drugs information & latest pharmacy news.

French Health Advisory Body Recommends Acomplia

Scope of reimbursement stated for Acomplia, by the transparency committee at the health authorities who have published their recommendation. Patients associated with obesity that is BMI greater than or equal to 30 kg/m2, with type 2 diabetes, insufficiently controlled by a mono therapy of metformin or sulfonylurea, with a HBA 1c level between 6.5% and 10% are known to benefit. Treatment of Acomplia is linked with a proper diet and physical activity.

Sanofi – Aventis
Backed by a world class R&D organization, Sanofi – Aventis is one of the worlds leading pharmaceutical companies. It is developing leading positions in seven major therapeutic areas which are cardiovascular, thrombosis, metabolic diseases, oncology, central nervous system, internal medicine and vaccines. Sanofi – Aventis has been listed in Paris as EURONEXT: SAN and in New York as NYSE: SNY.

Forward Looking Statements
Forward looking statements in this press release are defined as in the Private Securities Litigation Reform Act of 1995. Forward looking statements are not historical facts. These statements cover financial projections and include estimates and their underlying assumptions, statements regarding plans, expectations and objectives with respect to future events, products, operations, and services and statements in regard to future performance.

Forward Looking Statements are usually identified by words like “expect”, “believes”, “anticipates”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi - Aventis management believes that the expectations reflected in such forward looking statements are reasonable, investors are warned that forward looking statements and information are subject to various risks and uncertainties, many of which are extremely difficult to state and usually beyond the control of Sanofi – Aventis, that could be actual developments and actual results to differ materially from those expressed in or projected or implied by, the forward looking statements and developments. The risks and uncertainties include those discussed or identified in the public filings with the SEC and the AMF made by Sanofi Aventis, including those listed under “Cautionary Statement Regarding Forward looking statements” and “Risk factors” in Sanofi – Aventis annual report on form 20-F for the year ended December 31, 2005. Sanofi Aventis does not undertake any obligation to update or revise any forward-looking information or statements, other than as required by applicable law.